- Home
- GUTS vs RANI Comparison
GUTS vs RANI Comparison
Compare GUTS & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUTS
- RANI
- Stock Information
- Founded
- GUTS 2010
- RANI 2012
- Country
- GUTS United States
- RANI United States
- Employees
- GUTS N/A
- RANI N/A
- Industry
- GUTS
- RANI Medicinal Chemicals and Botanical Products
- Sector
- GUTS
- RANI Health Care
- Exchange
- GUTS NYSE
- RANI Nasdaq
- Market Cap
- GUTS 58.9M
- RANI 55.3M
- IPO Year
- GUTS 2024
- RANI 2021
- Fundamental
- Price
- GUTS $1.16
- RANI $1.25
- Analyst Decision
- GUTS Buy
- RANI Strong Buy
- Analyst Count
- GUTS 1
- RANI 6
- Target Price
- GUTS $10.00
- RANI $11.33
- AVG Volume (30 Days)
- GUTS 201.2K
- RANI 147.7K
- Earning Date
- GUTS 03-03-2025
- RANI 05-05-2025
- Dividend Yield
- GUTS N/A
- RANI N/A
- EPS Growth
- GUTS N/A
- RANI N/A
- EPS
- GUTS N/A
- RANI N/A
- Revenue
- GUTS $93,000.00
- RANI N/A
- Revenue This Year
- GUTS N/A
- RANI N/A
- Revenue Next Year
- GUTS N/A
- RANI N/A
- P/E Ratio
- GUTS N/A
- RANI N/A
- Revenue Growth
- GUTS N/A
- RANI N/A
- 52 Week Low
- GUTS $1.16
- RANI $1.24
- 52 Week High
- GUTS $7.89
- RANI $8.75
- Technical
- Relative Strength Index (RSI)
- GUTS 35.75
- RANI 32.62
- Support Level
- GUTS $1.19
- RANI $1.30
- Resistance Level
- GUTS $1.32
- RANI $1.56
- Average True Range (ATR)
- GUTS 0.09
- RANI 0.09
- MACD
- GUTS 0.00
- RANI -0.03
- Stochastic Oscillator
- GUTS 9.09
- RANI 1.39
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.